Pharmacy Disclosure Log 2024

1. Acute Myeloid Leukaemia Response 256
2. Atopic Dermatitis Response 472
3. Atopic Dermatitis Response 728
4. Allogeneic Stem Cell Transplants Response 268
5. Allogeneic Stem Cell Transplants Response 268 - Attachment
6. Alpha-1 Proteinase-Inhibitor Response 095
7. Ammonia Blood Testing Response 406
8. Asthma Response 235
9. Asthma Treatment Response 486
10. Biliary Tract and Non-Small Cell Lung Cancer Treatment Response 244
11. Biologic and Biosimilar Products Response 602
12. Biologic and Targeted Medications Response 720
13. Biologic and Targeted Medications Response 215
14. Biologic Medicines in Gastroenterology Response 573
15. Biologic Medicines in Gastroenterology Response 362
16. Biologic Medicines in Dermatology Response 022
17. Biologic Medicines in Dermatology Response 536
18. Biologic Medicines in Gastroenterology Response 076
19. Biologic and Biosimilar Response 295
20. Biologic Medicines in Dermatology Response 293
21. Blood Monitoring Devices Response 294
22. Blood Test Volumes Response 270
23. Botox Treatments Response 548
24. Breast Cancer Response 110
25. Breast Cancer Response 594
26. Cancer Treatment using Specified Products Response 379
27. Cancer Treatments Response 651
28. Chronic Lymphocytic Leukaemia Response 571
29. Colorectal Cancer Response 169
30. Colorectal Cancer Response 430
31. Diffuse Large B Cell Lymphoma Response 425
32. Dispensing and Prescribing Practices Response 616
33. Endometrial Cancer Response 427
34. Endometrial Cancer Response 668
35. GCA and HS Response 038
36. GCA and HS Response 038-Attachment1
37. Giant Cell Arteritis Response 301
38. Giant Cell Arteritis Response 8427 -Attachment
39. Haematology and Immunoglobulin Treatments Response175
40. Haematology and Immunoglobulin Treatments Response 414
41. Hidradenitis Suppurativa Response 429
42. Haematology and Immunoglobulin Treatments Response 659
43. Hidradenitis Suppurativa Response 429 - Attachment
44. High Acuity Monitoring Response 663
45. High Acuity Monitoring Response 663
46. HIV PrEP and HIV Treatment Response 698
47. Immunology Response 144
48. Intra-Vitreal Injections or Implants Response 028
49. Intra-Vitreal Injections or Implant Response 305
50. Intra-Vitreal Injections or Implants Response 545
51. Intravitreal Treatments for any Eye Condition Response 089
52. Intra-Vitreal Treatments Response 391
53. Intra-Vitreal Treatments for Eyes Response 619
54. Lactose intolerance medication Response 632
55. Lung Cancer Response 120
56. Lung Cancer Response 605
57. Medications within Dermatology Response 469
58. Metastatic Renal Cell Carcinoma Response 225
59. Meropenem Response 705
60. Migraine Response 188
61. Migraine Response 371
62. Migraine Response 578
63. Multiple Myeloma Response 273
64. Multiple Myeloma Response 649
65. Myasthenia Gravis Response 642
66. Myasthenia Gravis Response 642 - Attachment
67. Myelofibrosis Response 165
68. Myelofibrosis Response 165 -Attachment 1
69. Myelofibrosis Response 418
70. Myelofibrosis Response 418 - Attachment
71. Newly Diagnosed Patients with AML Response 503
72. Nitazenes and Fentanyls Response 693
73. Non-Small Cell Lung Cancer Response 374
74. Non-Small Cell Lung Cancer Response 715
75. Oncology Breast Cancer Response 358
76. Oncology Supplemental Response 180
77. Oncology Supplemental Response 438
78. Oncology Supplemental Response 680
79. Oncology Treatment by Therapies Response 292
80. Patients Treated for any Disease Response 337
81. Patients Treated for any Disease Response 337 - Attachment
82. Patients Treated with Specific Medicines Response 477
83. Patients Treated with Specific Medicines Response 477 - Attachment
84. Patients with Lupus Response 533
85. Pharmaceutical Companies Response 381
86. Posology of Enoxaparin Response 434
87. Prescription CBPMs Response 112
88. Spasmodic Torticollis Response 564
89. Starvation Ketoacidosis Response 445
90. Starvation Ketoacidosis Response 445 - Attachment
91. Renal Cell Carcinoma Response 192
92. Renal Cell Carcinoma Response 192 - Attachment
93. Renal Cell Carcinoma Response 383
94. Renal Cell Carcinoma Request 383 - Attachment
95. Renal Cell Carcinoma Response 597
96. Rheumatology Department Response 008
97. Treatment with Specified Products Response 047
98. Treatment of Cancers Response 212
99. Treatment of Cancer using a Specific Combination of Drugs Response 582
100. Treatment of Dermatological Conditions Response 219
101. Treatment for Myelofibrosis Response 681
102. Treatment for Myelofibrosis Response 681 Attachment
103. Urothelial and Endometrial Cancer Response 247
104. Vaccines Administered Response 689
105. Vaccines Administered Copy of Response 689 - Attachment
106. Waldenström Macroglobulinemia Patients Response 455
107. Wet Age-Related Macular Degeneration Response 617

 

 

• Share:
• Facebook
• Twitter
• LinkedIn